Atlas Trials

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Clinical trial NCT05342792 · RECRUITING

Trial details

NCT number
NCT05342792
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma
Start date
2022-04-17
Primary completion
2027-06-01
Enrollment
556

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.